← All trials
NCT02216383
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2015
- Primary completion
- Feb 1, 2017
- Completion date
- Feb 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 6285
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of BristolLead sponsor
- University of BristolCollaborator
- Gloucestershire Hospitals NHS Foundation TrustCollaborator
- FerringCollaborator
- University of the West of EnglandCollaborator
- University of BathCollaborator
- University of BristolStudy director
- University of BristolStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.